Abeona Therapeutics公司宣布,其针对X连锁视网膜劈裂症(XLRS)的Abo-503基因疗法已被美国食品药品监督管理局(FDA)选中,纳入罕见疾病终点推进(RDEA)试点项目。
Abeona Therapeutics公司宣布,其针对X连锁视网膜劈裂症(XLRS)的Abo-503基因疗法已被美国食品药品监督管理局(FDA)选中,纳入罕见疾病终点推进(RDEA)试点项目。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.